Strongbridge Biopharma plc (SBBP) financial statements (2022 and earlier)

Company profile

Business Address 900 NORTHBROOK DRIVE, SUITE 200
TREVOSE, PA 19053
State of Incorp.
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:87,52278,100122,49057,510
Cash and cash equivalents87,52257,032122,49057,510
Other undisclosed cash, cash equivalents, and short-term investments 21,068  
Receivables2,8012,2891,6261,584
Inventory, net of allowances, customer advances and progress billings1,1031,9933,946511
Inventory1,1031,9933,946511
Other undisclosed current assets9261,1614,2361,208
Total current assets:92,35283,543132,29860,813
Noncurrent Assets
Operating lease, right-of-use asset597789
Property, plant and equipment21629129415
Intangible assets, net (including goodwill)27,34432,36637,38842,411
Goodwill7,2567,2567,2567,256
Intangible assets, net (excluding goodwill)20,08825,11030,13235,155
Other noncurrent assets591649305686
Total noncurrent assets:28,74834,09537,98743,112
TOTAL ASSETS:121,100117,638170,285103,925
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities10,03720,96216,06511,232
Accrued liabilities3,12720,96216,06511,232
Employee-related liabilities5,749   
Taxes payable1,161   
Other undisclosed current liabilities11,0943,3311,1841,247
Total current liabilities:21,13124,29317,24912,479
Noncurrent Liabilities
Long-term debt and lease obligation17,779  37,794
Long-term debt, excluding current maturities17,114  37,794
Operating lease, liability665 
Liabilities, other than long-term debt7531,080  
Other liabilities7531,080  
Other undisclosed noncurrent liabilities15,83220,07440,08165,566
Total noncurrent liabilities:34,36421,15440,081103,360
Total liabilities:55,49545,44757,330115,839
Stockholders' equity
Stockholders' equity attributable to parent65,56172,147112,911(11,958)
Common stock672542541401
Additional paid in capital370,447332,085323,402230,524
Accumulated other comprehensive income 3  
Accumulated deficit(305,558)(260,483)(211,032)(242,883)
Other undisclosed stockholders' equity44444444
Total stockholders' equity:65,60572,191112,955(11,914)
TOTAL LIABILITIES AND EQUITY:121,100117,638170,285103,925

Income statement (P&L) ($ in thousands)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
Revenues30,73121,71218,0277,046
Revenue, net7,046
Cost of revenue(2,212)(3,822)(3,986)(1,483)
Cost of goods and services sold(2,212)(3,822) (1,483)
Gross profit:28,51917,89014,0415,563
Operating expenses(71,684)(84,983)(95,964)(79,305)
Operating loss:(43,165)(67,093)(81,923)(73,742)
Nonoperating income (expense)(1,925)19,410114,310(37,970)
Investment income, nonoperating  130,832 
Interest and debt expense(1,336) (21,000)(3,545)
Income (loss) from continuing operations before equity method investments, income taxes:(46,426)(47,683)11,387(115,257)
Other undisclosed income from continuing operations before income taxes1,336 21,0003,545
Income (loss) from continuing operations before income taxes:(45,090)(47,683)32,387(111,712)
Income tax expense (benefit)15(1,768)(536)(1,771)
Net income (loss) available to common stockholders, basic:(45,075)(49,451)31,851(113,483)
Other undisclosed net loss available to common stockholders, diluted (11,386)(16,337) 
Net income (loss) available to common stockholders, diluted:(45,075)(60,837)15,514(113,483)

Comprehensive Income ($ in thousands)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
Net income (loss):(45,075)(49,451)31,851(113,483)
Comprehensive income (loss):(45,075)(49,451)31,851(113,483)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(3)3  
Comprehensive income (loss), net of tax, attributable to parent:(45,078)(49,448)31,851(113,483)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: